These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Aglepristone (RU534) administration to non-pregnant bitches in the mid-luteal phase induces early luteal regression.
    Author: Polisca A, Scotti L, Orlandi R, Brecchia G, Maranesi M, Zerani M, Boiti C.
    Journal: Theriogenology; 2010 Sep 01; 74(4):672-81. PubMed ID: 20452002.
    Abstract:
    The effect of the antiprogestagen aglepristone (10 mg/kg bw), administered at days 29 and 30 following the estimated day of LH surge (day 0), on corpora lutea (CL) function was examined during the diestrus phase of non-pregnant bitches. Aglepristone shortened (P < 0.01) the luteal phase and complete luteolysis (progesterone <2 ng/mL) was observed at days 40.8 +/- 3.5 and 71.5 +/- 4.6 (means +/- SD; n = 9/group) in treated and control bitches, respectively. Peripheral estradiol-17beta concentrations declined from 91.5 +/- 14.3 pg/mL at day 9 to 50 pg/mL at day 18, remaining at approximately the same levels thereafter in both treated and control bitches. Intraluteal in vitro synthesis of progesterone and estradiol-17beta released by CL explanted at day 38 from control bitches (511.9 +/- 285.6 and 40.7 +/- 17.2 pg/mg protein, respectively) did not differ from that of treated. From day 38, intraovarian hemodynamic variables (arterial blood flow, systolic peak, and end-diastolic velocities), monitored by color-coded and pulsed Doppler, decreased more steeply (P < 0.01) in aglepristone-treated (n = 4) than in control (n = 4) bitches, whereas the resistance index increased (P < 0.01) in treated animals. All the blood flow parameters were undetectable at 60 +/- 3.6 and 68 +/- 2.0 days (medians +/- SD) after LH peak in treated and control bitches, respectively. In conclusion, aglepristone administration to dogs during the mid-luteal phase markedly accelerates the luteolytic process which is accompanied by a parallel decline in ovarian blood flow supply with a shift from approximately 8 to 10 days.
    [Abstract] [Full Text] [Related] [New Search]